Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 14, 2019 20:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 260 | $110.25 | $28,664.22 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.17 to $110.29. The price reported above reflects the weighted average sale price. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,391 | $109.70 | $701,086.31 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,597 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.17 to $110.16. The price reported above reflects the weighted average sale price. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 54.834 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:23 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,078.122 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-19-000111 · edgar.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,596.778 Underlying: Common Stock · 1,078.122 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:23 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $120.58 | $0.00 |
DisclosureSEC source: 0000911916-19-000111 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,362.609 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.154 phantom stock units accrued on April 30, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,506 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $100.82 | $670,553.82 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.45 to $101.07. The price reported above reflects the weighted average sale price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 23:03 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 186.67 | $0.00 Strike: $127.23 | $0.00 |
DisclosureSEC source: 0000911916-19-000099 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,851.455 Underlying: Common Stock · 186.67 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.965 phantom stock units accrued on January 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,157 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $101.05 | $672,083.55 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.89 to $101.20. The price reported above reflects the weighted average sale price. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:30 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | PurchaseCommon Stock | 2,000 | $123.62 | $247,249.60 |
DisclosureSEC source: 0000911916-19-000034 · edgar.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Represents the purchase of 2,000 shares in multiple transactions ranging in price from $123.614 to $123.63 per share, resulting in a weighted average purchase price of $123.6248. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,134 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · derivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,808 Underlying: ResMed Commmon Stock · 4,134 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 2,517 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · derivative · entry 6 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 2,517 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,134 | $97.22 | $401,911.61 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $97.05 to $97.41. The price reported above reflects the weighted average sale price. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,134 | $43.63 | $180,366.42 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,517 | $97.11 | $244,418.32 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $96.84 to $97.52. The price reported above reflects the weighted average sale price. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,517 | $43.63 | $109,816.71 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $113.75 | $756,551.25 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.38 to $114.07. The price reported above reflects the weighted average sale price. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:06 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001567619-19-001236 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:17 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 229.668 | $0.00 Strike: $103.41 | $0.00 |
DisclosureSEC source: 0000911916-19-000004 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,652.82 Underlying: Common Stock · 229.668 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 10.938 phantom stock units accrued on October 31, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 23:05 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 57,763 | $104.18 | $6,017,749.34 |
DisclosureSEC source: 0001567619-18-006951 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 23:05 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 103,558 | $104.18 | $10,788,672.44 |
DisclosureSEC source: 0001567619-18-006951 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,045 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on November 21, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,300 | $104.49 | $344,817.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Foundation Disclosed balance after: 0 Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Foundation Disclosed balance after: 3,300 F2 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. F3 · ownership.nature: Mr. and Mrs. Farrell retain dispositive power over foundation holdings. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Trust Disclosed balance after: 10,340 F2 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 16:58 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 13,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006729 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lissette and Michael Farrell Family Trust Disclosed balance after: 13,640 F1 · kind: Acquisition originates from a maturity distribution of the Charitable Income Trust II to beneficiaries. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:30 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 80,092 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006571 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,092 Underlying: ResMed Common Stock · 80,092 shares Expires 2025-11-14 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2019, 2020 and 2021. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 4,495 | $106.94 | $480,695.30 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,487 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,092 | $106.94 | $865,358.48 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,982 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:55 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,417 | $106.94 | $365,413.98 |
DisclosureSEC source: 0001567619-18-005879 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,074 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 199.72 shares of ResMed stock purchased on October 31, 2018, through the ResMed Employee Stock Purchase Plan Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:51 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 11,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004793 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,291 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 19:59 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 181.783 | $0.00 Strike: $130.65 | $0.00 |
DisclosureSEC source: 0000911916-18-000178 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,412.214 Underlying: Common Stock · 181.783 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 9.552 phantom stock units accrued on July 31, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 00:20 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 20,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001328 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,136 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 69.99 shares of ResMed stock purchased on April 30,2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 20:06 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 211.393 | $0.00 Strike: $112.35 | $0.00 |
DisclosureSEC source: 0000911916-18-000134 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,220.879 Underlying: Common Stock · 211.393 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:13 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,143.159 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-18-000122 · edgar.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,518.656 Underlying: Common Stock · 1,143.159 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:13 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $113.72 | $0.00 |
DisclosureSEC source: 0000911916-18-000122 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,009.486 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 8.839 phantom stock units accrued on April 30, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 19:10 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 218.672 | $0.00 Strike: $108.61 | $0.00 |
DisclosureSEC source: 0000911916-18-000105 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500.647 Underlying: Common Stock · 218.672 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 109.336 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 109.336 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 7.659 phantom stock units accrued on January 29, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 18:29 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 195.812 | $0.00 Strike: $121.29 | $0.00 |
DisclosureSEC source: 0000911916-18-000014 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,274.316 Underlying: Common Stock · 195.812 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: 97.906 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: 97.906 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 7.950 phantom stock units accrued on October 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 14,546 | $84.63 | $1,231,027.98 |
DisclosureSEC source: 0001140361-17-044015 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,395 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 27,876 | $84.63 | $2,359,145.88 |
DisclosureSEC source: 0001140361-17-044015 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,941 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:53 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 102,781 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001140361-17-043343 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,781 Underlying: ResMed Common Stock · 102,781 shares Expires 2024-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2018, 2019 and 2020. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 4,732 | $83.06 | $393,039.92 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,065 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,518 | $83.06 | $707,505.08 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,797 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 8,684 | $83.06 | $721,293.04 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,315 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F2 · balance_after: Includes 267 shares of ResMed stock purchased on Oct 31, 2017, through the ResMed Employee Stock Purchase Plan Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 23:50 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 3,300 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-040605 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,300 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 23:50 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 3,300 | $33.70 | $111,210.00 |
DisclosureSEC source: 0001140361-17-040605 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. F2 · shares: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:31 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 14,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038519 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,432 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.